title: Update on thrombotic thrombocytopenic purpura.
abstract: Thrombotic thrombocytopenic purpura (TTP) is a thrombotic microangiopathy, which is classically associated with signs and symptoms of fever, thrombocytopenia, neurologic deficits, hemolytic anemia, and renal failure. It is caused by a deficiency of A Disintegrin-like And Metalloprotease with a ThromboSpondin type1 motif 13 (ADAMTS13), which may be an inherited disorder, but more commonly is an acquired disease due to autoantibodies directed against ADAMTS13. Low ADAMTS13 levels result in increased ultra-large von Willebrand factor multimers, which induce platelet adhesion and thrombosis. Plasma exchange therapy is the standard of care, and has greatly reduced morbidity and mortality. A recent TTP case is reviewed, and treatments for recurrent or refractory TTP are summarized. A scoring system using clinical and laboratory parameters to evaluate which suspected TTP patients will benefit from plasma exchange therapy is also discussed.
authors.affiliation: Department of Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah 84111, USA. dane.osborn@hsc.utah.edu
authors.forename: J Dane
authors.initials: JD
authors.lastname: Osborn
authors.forename: George M
authors.initials: GM
authors.lastname: Rodgers
mesh_terms: D000293:Adolescent; D000328:Adult; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D011247:Pregnancy; D011379:Prognosis; D011697:Purpura, Thrombotic Thrombocytopenic / Q000175:diagnosis* / Q000628:therapy*